Document Detail


Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes.
MedLine Citation:
PMID:  20590617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: A main challenge in the therapy of osteoarthritis (OA) is the development of drugs that will modify the disease. Reliable test systems are necessary to enable an efficient screening of therapeutic substances. We therefore established a chondrocyte-based in vitro cell culture model in order to characterize different p38MAPK inhibitors.
EXPERIMENTAL APPROACH: Interleukin-1beta (IL-1beta)-stimulated human OA chondrocytes were treated with the p38MAPK inhibitors Birb 796, pamapimod, SB203580 and the new substance CBS-3868. Birb 796- and SB203580-treated cells were analysed in a genome-wide microarray analysis. The efficacy of all inhibitors was characterized by quantitative gene expression analysis and the quantification of PGE(2) and NO release.
KEY RESULTS: Microarray analysis revealed inhibitor-specific differences in gene expression. Whereas SB203580 had a broad effect on chondrocytes, Birb 796 counteracted the IL-1beta effect more specifically. All p38MAPK inhibitors significantly inhibited the IL-1beta-induced gene expression of COX-2, mPGES1, iNOS, matrix metalloproteinase 13 (MMP13) and TNFRSF11B, as well as PGE(2) release. Birb 796 and CBS-3868 showed a higher efficacy than SB203580 and pamapimod at inhibiting the expression of COX-2 and MMP13 genes, as well as PGE(2) release. In the case of mPGES1 and TNFRSF11B gene expression, CBS-3868 exceeded the efficacy of Birb 796.
CONCLUSIONS AND IMPLICATIONS: Our test system could differentially characterize inhibitors of the same primary pharmaceutical target. It reflects processes relevant in OA and is based on chondrocytes that are mainly responsible for cartilage degradation. It therefore represents a valuable tool for drug screening in between functional in vitro testing and in vivo models.
Authors:
H Joos; W Albrecht; S Laufer; R E Brenner
Related Documents :
9893257 - Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth an...
19539797 - Identification of differentially expressed genes between osteoblasts and osteocytes.
8387797 - Collagens and their abnormalities in a wide spectrum of diseases.
18957417 - Regulation of cartilage-specific gene expression in human chondrocytes by sirt1 and nic...
1623257 - Tics and myoclonus.
12788657 - Lentiviral vectors with two independent internal promoters transfer high-level expressi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  160     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-01     Completed Date:  2010-10-07     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1252-62     Citation Subset:  IM    
Affiliation:
Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, Ulm, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Culture Techniques
Chondrocytes / drug effects*,  metabolism*
Dinoprostone / metabolism
Drug Evaluation, Preclinical / methods*
Gene Expression / drug effects*
Humans
Inflammation Mediators / metabolism*
Interleukin-1beta / antagonists & inhibitors*,  pharmacology
Nitric Oxide / metabolism
Oligonucleotide Array Sequence Analysis / methods
Protein Kinase Inhibitors / pharmacology*
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Inflammation Mediators; 0/Interleukin-1beta; 0/Protein Kinase Inhibitors; 10102-43-9/Nitric Oxide; 363-24-6/Dinoprostone; EC 2.7.11.24/p38 Mitogen-Activated Protein Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY72...
Next Document:  The role of nitric oxide, superoxide and peroxynitrite in the anti-arrhythmic effects of preconditio...